We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > HSDD

News List

Cannabinoid topical cream for treatment of Female Hypoactive Sexual Desire Disorder europeanpharmaceuticalreview
April 22, 2019
Pivot Pharmaceuticals Inc. is to begin human clinical trials of PVT-005, the pharmaceutical drug candidate for the treatment of HSDD…
AMAG's Label Expansion of Lead Products Raises Share Price nasdaq
November 27, 2018
Share price of AMAG Pharmaceuticals, Inc. AMAG has increased 37.9% year to date...
Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women biospace
March 27, 2018
NDA includes data from two successful Phase 3 trials in HSDD in premenopausal women in which bremelanotide met the pre-specified co-primary efficacy endpoints